Andrew D. Campbell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrew D. Campbell has a total of 531 co-authors. Here are the top co-authors by number of shared publications:
- Owen James Sansom
School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
122 shared publications - Colin Nixon
Cancer Research UK Scotland Institute, Glasgow, United Kingdom
102 shared publications - Kathryn Gilroy
Cancer Research UK Scotland Institute, Glasgow, United Kingdom
98 shared publications - Tamsin R. M. Lannagan
Cancer Research UK Scotland Institute, Glasgow, UK
59 shared publications - Rene Jackstadt
Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGMBH), Heidelberg, Germany
58 shared publications - Rachel A. Ridgway
Cancer Research UK Scotland Institute, Glasgow, UK
51 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S10 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
Supplementary Figures S1-S10 with associated figure legends.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S10 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
Supplementary Figures S1-S10 with associated figure legends.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of wild-type KRAS sensitizes KPC KrasG12D/fl tumours to MEK1/2 inhibition.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of wild-type KRAS sensitizes KPC KrasG12D/fl tumours to MEK1/2 inhibition.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Acceleration of pancreatic tumour initiation after loss of wild-type Kras in KPC KrasG12D/fl mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Acceleration of pancreatic tumour initiation after loss of wild-type Kras in KPC KrasG12D/fl mice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Release from AZD6244 treatment results in rapid acinar to ductal metaplasia in KC KrasG12D/fl.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Release from AZD6244 treatment results in rapid acinar to ductal metaplasia in KC KrasG12D/fl.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Increased fibrosis in wild-type Kras deficient PanINs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Increased fibrosis in wild-type Kras deficient PanINs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
MEK1/2 inhibition in KPC KrasG12D/fl mice with established tumours reverses enrichment of immune response related gene programmes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
MEK1/2 inhibition in KPC KrasG12D/fl mice with established tumours reverses enrichment of immune response related gene programmes.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
Reverse Phase Protein Array antibodies
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
Reverse Phase Protein Array antibodies
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of wild-type KRAS does not alter PI3K-AKT signalling.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of wild-type KRAS does not alter PI3K-AKT signalling.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
Cotargeting of MEK1/2 and the RAC1 effector p110β suppresses growth of melanoma lines in vitro. A, Left, relative confluence of WM266.4 cells treated with indicated treatments over time. Representative of a minimum of five independent experiments and three technical replicates. Data, mean ± SEM (confluence relative to starting point). Right, relative change in confluence of WM266.4 cells over indicated 72-hour treatment. Center line, mean. P values calculated by one-way ANOVA corrected for multiple comparisons (Tukey). B, Left, relative confluence of A375 cells treated with indicated treatments over time. Representative of three independent experiments with a minimum of three technical replicates. Data, mean ± SEM (confluence relative to starting point). Right, relative change in confluence of A375 cells over indicated 72-hour treatment. Center line, mean. P values calculated by one-way ANOVA corrected for multiple comparisons (Tukey). C, Fluorescence labeled (LI-COR) immunoblotting for indicated activated components of the MAPK–PI3K–mTOR pathway in the indicated human melanoma cells treated with vehicle or the indicated targeted therapeutics. Co-labeled total protein detection for each phosphoprotein serves as a sample integrity control. The blots are representative of three repeated experiments. D, RPPA dataset comparing PTEN-deficient and PTEN-proficient melanoma cell lines treated with indicated treatments for 24 hours. Cell line names and treatments are indicated below the heatmap. Antigens, detected by RPPA antibodies, are listed vertically according to biological process/signaling pathway. Color intensity scale indicates high (red) and low (blue) log2FC of RPPA intensity values relative to the relevant DMSO control. Results are representative of two technical and five biological replicates per condition.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
Cotargeting of MEK1/2 and the RAC1 effector p110β suppresses growth of melanoma lines in vitro. A, Left, relative confluence of WM266.4 cells treated with indicated treatments over time. Representative of a minimum of five independent experiments and three technical replicates. Data, mean ± SEM (confluence relative to starting point). Right, relative change in confluence of WM266.4 cells over indicated 72-hour treatment. Center line, mean. P values calculated by one-way ANOVA corrected for multiple comparisons (Tukey). B, Left, relative confluence of A375 cells treated with indicated treatments over time. Representative of three independent experiments with a minimum of three technical replicates. Data, mean ± SEM (confluence relative to starting point). Right, relative change in confluence of A375 cells over indicated 72-hour treatment. Center line, mean. P values calculated by one-way ANOVA corrected for multiple comparisons (Tukey). C, Fluorescence labeled (LI-COR) immunoblotting for indicated activated components of the MAPK–PI3K–mTOR pathway in the indicated human melanoma cells treated with vehicle or the indicated targeted therapeutics. Co-labeled total protein detection for each phosphoprotein serves as a sample integrity control. The blots are representative of three repeated experiments. D, RPPA dataset comparing PTEN-deficient and PTEN-proficient melanoma cell lines treated with indicated treatments for 24 hours. Cell line names and treatments are indicated below the heatmap. Antigens, detected by RPPA antibodies, are listed vertically according to biological process/signaling pathway. Color intensity scale indicates high (red) and low (blue) log2FC of RPPA intensity values relative to the relevant DMSO control. Results are representative of two technical and five biological replicates per condition.